Financhill
Sell
42

SRPT Quote, Financials, Valuation and Earnings

Last price:
$36.26
Seasonality move :
13.8%
Day range:
$35.46 - $38.03
52-week range:
$35.46 - $173.25
Dividend yield:
0%
P/E ratio:
20.50x
P/S ratio:
1.82x
P/B ratio:
3.14x
Volume:
9.2M
Avg. volume:
3.8M
1-year change:
-72.45%
Market cap:
$3.6B
Revenue:
$1.9B
EPS (TTM):
-$2.69

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SRPT
Sarepta Therapeutics
$684.1M -$0.65 53.26% 1978.57% $100.92
AMGN
Amgen
$8B $4.26 5.5% 281.73% $315.35
BMRN
Biomarin Pharmaceutical
$738.7M $0.95 6.98% 86.93% $96.02
EWTX
Edgewise Therapeutics
-- -$0.42 -- -27.65% $42.20
MRNA
Moderna
$115.3M -$3.11 -49.84% -11.55% $46.96
VRTX
Vertex Pharmaceuticals
$2.9B $4.29 9.83% 1.98% $500.30
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SRPT
Sarepta Therapeutics
$36.52 $100.92 $3.6B 20.50x $0.00 0% 1.82x
AMGN
Amgen
$272.05 $315.35 $146.3B 24.82x $2.38 3.36% 4.31x
BMRN
Biomarin Pharmaceutical
$59.82 $96.02 $11.5B 22.24x $0.00 0% 4.01x
EWTX
Edgewise Therapeutics
$14.70 $42.20 $1.4B -- $0.00 0% --
MRNA
Moderna
$24.38 $46.96 $9.4B -- $0.00 0% 3.02x
VRTX
Vertex Pharmaceuticals
$429.60 $500.30 $110.3B 26.10x $0.00 0% 10.02x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SRPT
Sarepta Therapeutics
49.9% 3.156 18.15% 2.06x
AMGN
Amgen
90.24% 0.239 34.26% 0.74x
BMRN
Biomarin Pharmaceutical
9.32% -0.133 4.39% 3.20x
EWTX
Edgewise Therapeutics
-- 1.971 -- --
MRNA
Moderna
-- 0.406 -- 3.92x
VRTX
Vertex Pharmaceuticals
-- 0.843 -- 2.12x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SRPT
Sarepta Therapeutics
$607.3M -$300.4M -10.44% -20.94% -50.88% -$629.3M
AMGN
Amgen
$5.2B $1.2B 8.85% 97.08% 33.08% $980M
BMRN
Biomarin Pharmaceutical
$593.6M $223.9M 8.4% 9.62% 32.34% $157.6M
EWTX
Edgewise Therapeutics
-- -$45.5M -- -- -- -$27.2M
MRNA
Moderna
$17M -$1.1B -29.23% -29.23% -900% -$1.2B
VRTX
Vertex Pharmaceuticals
$2.4B $1B -6.04% -6.04% 26.48% $778.2M

Sarepta Therapeutics vs. Competitors

  • Which has Higher Returns SRPT or AMGN?

    Amgen has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of 21.23%. Sarepta Therapeutics's return on equity of -20.94% beat Amgen's return on equity of 97.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
    AMGN
    Amgen
    63.58% $3.20 $63.6B
  • What do Analysts Say About SRPT or AMGN?

    Sarepta Therapeutics has a consensus price target of $100.92, signalling upside risk potential of 179.64%. On the other hand Amgen has an analysts' consensus of $315.35 which suggests that it could grow by 15.92%. Given that Sarepta Therapeutics has higher upside potential than Amgen, analysts believe Sarepta Therapeutics is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRPT
    Sarepta Therapeutics
    14 5 0
    AMGN
    Amgen
    9 14 2
  • Is SRPT or AMGN More Risky?

    Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Amgen has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.829%.

  • Which is a Better Dividend Stock SRPT or AMGN?

    Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.36% to investors and pays a quarterly dividend of $2.38 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios SRPT or AMGN?

    Sarepta Therapeutics quarterly revenues are $744.9M, which are smaller than Amgen quarterly revenues of $8.1B. Sarepta Therapeutics's net income of -$447.5M is lower than Amgen's net income of $1.7B. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Amgen's PE ratio is 24.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.82x versus 4.31x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRPT
    Sarepta Therapeutics
    1.82x 20.50x $744.9M -$447.5M
    AMGN
    Amgen
    4.31x 24.82x $8.1B $1.7B
  • Which has Higher Returns SRPT or BMRN?

    Biomarin Pharmaceutical has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of 24.92%. Sarepta Therapeutics's return on equity of -20.94% beat Biomarin Pharmaceutical's return on equity of 9.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
    BMRN
    Biomarin Pharmaceutical
    79.66% $0.95 $6.4B
  • What do Analysts Say About SRPT or BMRN?

    Sarepta Therapeutics has a consensus price target of $100.92, signalling upside risk potential of 179.64%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.02 which suggests that it could grow by 60.51%. Given that Sarepta Therapeutics has higher upside potential than Biomarin Pharmaceutical, analysts believe Sarepta Therapeutics is more attractive than Biomarin Pharmaceutical.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRPT
    Sarepta Therapeutics
    14 5 0
    BMRN
    Biomarin Pharmaceutical
    16 6 0
  • Is SRPT or BMRN More Risky?

    Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

  • Which is a Better Dividend Stock SRPT or BMRN?

    Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRPT or BMRN?

    Sarepta Therapeutics quarterly revenues are $744.9M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Sarepta Therapeutics's net income of -$447.5M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Biomarin Pharmaceutical's PE ratio is 22.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.82x versus 4.01x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRPT
    Sarepta Therapeutics
    1.82x 20.50x $744.9M -$447.5M
    BMRN
    Biomarin Pharmaceutical
    4.01x 22.24x $745.1M $185.7M
  • Which has Higher Returns SRPT or EWTX?

    Edgewise Therapeutics has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of --. Sarepta Therapeutics's return on equity of -20.94% beat Edgewise Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
    EWTX
    Edgewise Therapeutics
    -- -$0.42 --
  • What do Analysts Say About SRPT or EWTX?

    Sarepta Therapeutics has a consensus price target of $100.92, signalling upside risk potential of 179.64%. On the other hand Edgewise Therapeutics has an analysts' consensus of $42.20 which suggests that it could grow by 187.08%. Given that Edgewise Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Edgewise Therapeutics is more attractive than Sarepta Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRPT
    Sarepta Therapeutics
    14 5 0
    EWTX
    Edgewise Therapeutics
    5 2 0
  • Is SRPT or EWTX More Risky?

    Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock SRPT or EWTX?

    Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRPT or EWTX?

    Sarepta Therapeutics quarterly revenues are $744.9M, which are larger than Edgewise Therapeutics quarterly revenues of --. Sarepta Therapeutics's net income of -$447.5M is lower than Edgewise Therapeutics's net income of -$39.7M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.82x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRPT
    Sarepta Therapeutics
    1.82x 20.50x $744.9M -$447.5M
    EWTX
    Edgewise Therapeutics
    -- -- -- -$39.7M
  • Which has Higher Returns SRPT or MRNA?

    Moderna has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of -907.48%. Sarepta Therapeutics's return on equity of -20.94% beat Moderna's return on equity of -29.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
    MRNA
    Moderna
    15.89% -$2.52 $10.1B
  • What do Analysts Say About SRPT or MRNA?

    Sarepta Therapeutics has a consensus price target of $100.92, signalling upside risk potential of 179.64%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 92.62%. Given that Sarepta Therapeutics has higher upside potential than Moderna, analysts believe Sarepta Therapeutics is more attractive than Moderna.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRPT
    Sarepta Therapeutics
    14 5 0
    MRNA
    Moderna
    5 17 1
  • Is SRPT or MRNA More Risky?

    Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

  • Which is a Better Dividend Stock SRPT or MRNA?

    Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRPT or MRNA?

    Sarepta Therapeutics quarterly revenues are $744.9M, which are larger than Moderna quarterly revenues of $107M. Sarepta Therapeutics's net income of -$447.5M is higher than Moderna's net income of -$971M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.82x versus 3.02x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRPT
    Sarepta Therapeutics
    1.82x 20.50x $744.9M -$447.5M
    MRNA
    Moderna
    3.02x -- $107M -$971M
  • Which has Higher Returns SRPT or VRTX?

    Vertex Pharmaceuticals has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of 23.33%. Sarepta Therapeutics's return on equity of -20.94% beat Vertex Pharmaceuticals's return on equity of -6.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
    VRTX
    Vertex Pharmaceuticals
    86.9% $2.49 $16.5B
  • What do Analysts Say About SRPT or VRTX?

    Sarepta Therapeutics has a consensus price target of $100.92, signalling upside risk potential of 179.64%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 16.46%. Given that Sarepta Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRPT
    Sarepta Therapeutics
    14 5 0
    VRTX
    Vertex Pharmaceuticals
    14 14 1
  • Is SRPT or VRTX More Risky?

    Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

  • Which is a Better Dividend Stock SRPT or VRTX?

    Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRPT or VRTX?

    Sarepta Therapeutics quarterly revenues are $744.9M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Sarepta Therapeutics's net income of -$447.5M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.82x versus 10.02x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRPT
    Sarepta Therapeutics
    1.82x 20.50x $744.9M -$447.5M
    VRTX
    Vertex Pharmaceuticals
    10.02x 26.10x $2.8B $646.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Spotify a Millionaire-Maker Stock?
Is Spotify a Millionaire-Maker Stock?

Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…

What Is a Millionaire-Maker Stock?
What Is a Millionaire-Maker Stock?

From time to time, investors will run across the term…

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
99
DAVE alert for May 9

Dave [DAVE] is up 9.31% over the past day.

Buy
52
QDEL alert for May 9

QuidelOrtho [QDEL] is down 0.22% over the past day.

Buy
61
TPC alert for May 9

Tutor Perini [TPC] is up 9.61% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock